Ashish M. Kamat/euoncology.europeanurology.com
May 26, 2025, 18:05
Ashish Kamat: Molecular Profiling of 99 Cases of Micropapillary Urothelial Carcinoma
Ashish Kamat, Professor and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, shared a post on X about a paper he co-authored published in Human Pathology:
“Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC):
Most common mutations: TP53, TERT, ARID1A, ERBB2
ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F)
Only ERBB2 amplifications associated with: HER2 overexpression, significantly worse overall survival (p=0.043)
MPUC tumors are luminal in origin and share features with conventional UC – but with distinct biology and clinical behavior.
Implication: Molecular profiling should be standard for MPUC. ERBB2 amplifications – not just mutations -may identify patients who need intensified or targeted therapy.”
Title: Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing
Authors: Yuan Shen, Lan Zheng, Jianping Zhao, Yishan Wang, Hui Chen, Sinchita Roy-Chowdhuri, Ashish M. Kamat, Omar Alhalabi, Jianjun Gao, Arlene Siefker-Radtke, Peng Wei, Donna E. Hansel, Bogdan Czerniak, Charles C. Guo
You can read the Full Article in Human Pathology.
More posts featuring Ashish Kamat.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 26, 2025, 16:27
May 26, 2025, 16:02
May 26, 2025, 15:37